For the year ending 2025-12-31, SPRY made $84,278K in revenue. -$171,393K in net income. Net profit margin of -203.37%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Total revenue | 84,278 | |||
| Cost of goods sold (including related party amounts of 4,781 and 241, respectively) | 20,423 | |||
| Research and development (including related party amounts of 2,255 and 2,066, respectively) | 13,181 | |||
| Selling, general and administrative (including related party amounts of 475 and 465, respectively) | 230,122 | |||
| Total operating expenses | 263,726 | |||
| Loss from operations | -179,448 | |||
| Interest income | 10,669 | |||
| Interest expense (including related party amounts of 130 and 0, respectively) | 2,599 | |||
| Total other income, net | 8,070 | |||
| (loss) income before income tax (benefit) expense | -171,378 | |||
| Income tax (benefit) expense | -80 | |||
| Net (loss) income | -171,298 | |||
| Unrealized (losses) gains on available-for-sale securities | -95 | |||
| Comprehensive (loss) income | -171,393 | |||
| Basic EPS | -1.74 | |||
| Diluted EPS | -1.74 | |||
| Basic Average Shares | 98,566,481 | |||
| Diluted Average Shares | 98,566,481 | |||
ARS Pharmaceuticals, Inc. (SPRY)
ARS Pharmaceuticals, Inc. (SPRY)